Stout announced that its client, Synaptikon GmbH has secured another financing round to accelerate its European growth strategy. Stout acted as the exclusive financial advisor to the founders and shareholders in this transaction.

Based in Berlin, Synaptikon GmbH, known under ‘NeuroNation’, is a European leader in the field of digital multi-domain brain training solutions to prevent and mitigate cognitive decline through its unique and evidently proven technology that is recommended by numerous clinical studies and healthcare professionals around the world.

Founded by Jakob Futorjanski and Rojahn Ahmadi, NeuroNation is a digital health company, specializing in digital therapies and machine learning to aid millions of people to regain, maintain, and improve cognitive and mental health. By collaborating with leading universities and institutions on a global scale (maintainyourbrain.org and agewell.de trial), the company integrates cooperative studies with the latest research findings into the training. This allowed the platform, available in 9 languages, to develop into a leading digital health care provider with more than 20 million users.

Supported by the German Ministry of Research in several projects and in collaboration with clinicians and researchers worldwide, the company is currently running a RCT to create evidence for a treatment for mild cognitive disorder and post-COVID patients. NeuroNation’s goal is to bring awareness to the importance of cognitive fitness and to highlight the significant impact it will have towards a positive change in the world.

For people who suffered a stroke or are suffering from neurodegenerative diseases, this digital therapy makes it possible to strengthen cognition and slow down the progression of the disease. NeuroNation is available worldwide via web and its mobile applications.

Jakob Futorjanski, Founder and CEO of Synaptikon, commented, “IMPACT Partners shares our goal of improving the mental health of millions of users and patients around the world with our evidently proven technology. We would like to thank the Stout Berlin team for their trusted advice, relentless effort, and global approach in order to successfully identify the ideal partner for us.”

Mathis Wilke, Managing Director at Stout, stated, “We are truly impressed with what Jakob, Rojahn and their team have built and accomplished so far. The growing demand for solutions in preventing and solving mental disorders, further fuelled by COVID-19, underlines NeuroNation’s mission of accelerating global growth, supported by IMPACT Partners.”

Stout’s Director Kevin Kissner assisted on the deal with further support from Associate Nansi Nistorova.

See more information on our Investment Banking services.